Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6027514 | 0.88 | KCNH2 (0.38) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6027811 | 0.87 | HPGD (0.39) | TP53 | |
| SCHEMBL6027551 | 0.74 | MAPT (0.40) | TP53 | |
| SCHEMBL4914828 | 0.70 | CYP3A4 (0.41) | KCNH2PIK3CDCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15122404 | 0.68 | GABRA1 (0.46) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8443520 | 0.63 | PTGS2 (0.43) | KCNH2SCN5ACYP3A4 | |
| SCHEMBL2868352 | 0.61 | SCN5A (0.50) | KCNH2SCN5ACYP3A4 | |
| Methylamine SCHEMBL27931104 | 0.61 | GABRA1 (0.46) | KCNH2SCN5ACYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL2868350 | 0.60 | PTGS2 (0.49) | KCNH2SCN5ACYP3A4 | |
| SCHEMBL22442946 | 0.60 | HTR1B (0.42) | TSHRCYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194782-A1 | Pharmacologically active imidazo[4,5-c] pyridines | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1670795-A1 | PHARMACOLOGICALLY ACTIVE IMIDAZO 4,5-C PYRIDINES | ALTANA Pharma AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005026164-A1 | PHARMACOLOGICALLY ACTIVE IMIDAZO[4,5-C]PYRIDINES | ALTANA PHARMA AG (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194782-A1 | Pharmacologically active imidazo[4,5-c] pyridines | GIPR, VIP, PGC | TSHR 1113/4885KCNH2 270/4885SCN5A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.